Priority COVID-19 Vaccination for Patients with Cancer While Vaccine Supply Is Limited

Overview

Journal Cancer Discov

Specialty Oncology

Date 2020 Dec 23

PMID 33355178

Citations 136

Authors

Antoni Ribas

Rajarshi Sengupta

Trevan Locke

Sayyed Kaleem Zaidi

Katie M Campbell

John M Carethers

Elizabeth M Jaffee

E John Wherry

Jean-Charles Soria

Gypsyamber DSouza

Affiliations

Soon will be listed here.

Abstract

Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.

Citing Articles

Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.

Spehner L, Orillard E, Falcoz A, Lepiller Q, Bouard A, Almotlak H BMJ Oncol. 2025; 2(1):e000054.

PMID: 39886486 PMC: 11235023. DOI: 10.1136/bmjonc-2023-000054.

Is COVID-19 Vaccination Beneficial for Tumor Patients: A Cross-Sectional Investigation in China.

Wang S, Zhu Y, Chen T, Lin C, Chen L, Niu Y Immun Inflamm Dis. 2024; 12(11):e70069.

PMID: 39601455 PMC: 11600451. DOI: 10.1002/iid3.70069.

Prognostic model for gastric cancer patients with COVID-19 and network pharmacology study on treatment by lentinan.

Zhou S, Sun H Sci Rep. 2024; 14(1):24645.

PMID: 39428405 PMC: 11491479. DOI: 10.1038/s41598-024-76783-2.

Low booster uptake in cancer patients despite health benefits.

Figueiredo J, Levy J, Choi S, Xu A, Merin N, Hamid O iScience. 2024; 27(9):110596.

PMID: 39286512 PMC: 11404159. DOI: 10.1016/j.isci.2024.110596.

mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.

Gangaev A, van Sleen Y, Brandhorst N, Hoefakker K, Prajapati B, Singh A Front Immunol. 2024; 15:1447555.

PMID: 39257577 PMC: 11385311. DOI: 10.3389/fimmu.2024.1447555.

References

Pinato D, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R . Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov. 2020; . PMC: 7668225. DOI: 10.1158/2159-8290.CD-20-0773. View

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z . Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020; 10(6):783-791. PMC: 7309152. DOI: 10.1158/2159-8290.CD-20-0422. View

Brar G, Pinheiro L, Shusterman M, Swed B, Reshetnyak E, Soroka O . COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study. J Clin Oncol. 2020; 38(33):3914-3924. PMC: 7676890. DOI: 10.1200/JCO.20.01580. View

Saini K, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M . Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020; 139:43-50. PMC: 7467090. DOI: 10.1016/j.ejca.2020.08.011. View

Kuderer N, Choueiri T, Shah D, Shyr Y, Rubinstein S, Rivera D . Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020; 395(10241):1907-1918. PMC: 7255743. DOI: 10.1016/S0140-6736(20)31187-9. View

Williamson E, Walker A, Bhaskaran K, Bacon S, Bates C, Morton C . Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584(7821):430-436. PMC: 7611074. DOI: 10.1038/s41586-020-2521-4. View

Lee L, Cazier J, Starkey T, Briggs S, Arnold R, Bisht V . COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020; 21(10):1309-1316. PMC: 7444972. DOI: 10.1016/S1470-2045(20)30442-3. View

Fillmore N, La J, Szalat R, Tuck D, Nguyen V, Yildirim C . Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. J Natl Cancer Inst. 2020; 113(6):691-698. PMC: 7665587. DOI: 10.1093/jnci/djaa159. View

Jee J, Foote M, Lumish M, Stonestrom A, Wills B, Narendra V . Chemotherapy and COVID-19 Outcomes in Patients With Cancer. J Clin Oncol. 2020; 38(30):3538-3546. PMC: 7571792. DOI: 10.1200/JCO.20.01307. View

10.

Robilotti E, Babady N, Mead P, Rolling T, Perez-Johnston R, Bernardes M . Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020; 26(8):1218-1223. PMC: 7785283. DOI: 10.1038/s41591-020-0979-0. View

11.

Zhang H, Han H, He T, Labbe K, Hernandez A, Chen H . Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2020; 113(4):371-380. PMC: 7665647. DOI: 10.1093/jnci/djaa168. View

12.

Ruthrich M, Giessen-Jung C, Borgmann S, Classen A, Dolff S, Gruner B . COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol. 2020; 100(2):383-393. PMC: 7648543. DOI: 10.1007/s00277-020-04328-4. View

13.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

14.

Gudbjartsson D, Norddahl G, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E . Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020; 383(18):1724-1734. PMC: 7494247. DOI: 10.1056/NEJMoa2026116. View

15.

Wang Q, Berger N, Xu R . When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities. Blood Rev. 2020; 47:100775. PMC: 7833659. DOI: 10.1016/j.blre.2020.100775. View

16.

Lee L, Cazier J, Angelis V, Arnold R, Bisht V, Campton N . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395(10241):1919-1926. PMC: 7255715. DOI: 10.1016/S0140-6736(20)31173-9. View

17.

Dooling K, McClung N, Chamberland M, Marin M, Wallace M, Bell B . The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(49):1857-1859. PMC: 7737687. DOI: 10.15585/mmwr.mm6949e1. View

18.

Rivera D, Peters S, Panagiotou O, Shah D, Kuderer N, Hsu C . Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discov. 2020; 10(10):1514-1527. PMC: 7541683. DOI: 10.1158/2159-8290.CD-20-0941. View

19.

Lara O, OCearbhaill R, Smith M, Sutter M, Knisely A, McEachron J . COVID-19 outcomes of patients with gynecologic cancer in New York City. Cancer. 2020; 126(19):4294-4303. PMC: 8654115. DOI: 10.1002/cncr.33084. View

20.

Lunski M, Burton J, Tawagi K, Maslov D, Simenson V, Barr D . Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana. Cancer. 2020; 127(2):266-274. DOI: 10.1002/cncr.33243. View